Developing new biopharmaceutical products for infectious diseases
Official title: Preclinical Services for Biopharmaceutical Product Development
Funded at Dynport Vaccine Company, LLC · NIH-10934723 · Data updated 2026-11-12
This study is working on creating new medicines, like antibodies and special RNA treatments, to help fight infections, and it's designed for people who are looking for better options to treat their health conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dynport Vaccine Company, LLC NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project start | September 8, 2023 |
| Project end | September 7, 2030 |
| Funding year | 2023 |
| Award (this year) | $1,079 |
| NIH project number | 75N93023D00008-0-759302300001-2 |
| Project ID | NIH-10934723 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from infectious diseases who may benefit from novel biopharmaceutical therapies.
✕Less likely to help
Patients with non-infectious diseases or those who do not respond to biopharmaceutical treatments may not receive benefits from this research.
What this research studies
This research focuses on the preclinical development of biopharmaceutical products, including monoclonal antibodies, recombinant proteins, and nucleic acid-based vectors like small interfering RNA (siRNA). The program offers services such as product development planning, assay development, and regulatory support to ensure that these innovative therapies can effectively combat infectious diseases. By advancing translational research, the project aims to bridge the gap between laboratory discoveries and clinical applications, ultimately leading to new treatment options for patients.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and effective treatments for infectious diseases.
How similar studies have gone: Other research in the field of biopharmaceutical development has shown success in creating effective therapies, indicating that this approach has potential for significant advancements.
Where this research is happening
-
Dynport Vaccine Company, LLC
Frederick, United States Active
Related research
Other NIH-funded projects on the same topics.
-
Investigating new treatments for infectious diseases through early phase clinical trials
This study is looking for people to join clinical trials that test new treatments for infectious diseases, with the hope of finding safer and more effective options to help patients like you.
-
Developing new treatments to combat bacterial resistance using biopharmaceuticals
This study is working on new treatments to help fight infections caused by bacteria that don't respond to regular antibiotics, and it's designed for patients who need better options for their infections.
-
Developing tests to detect and identify infectious bacteria
This study is working on better tests to quickly and accurately find harmful bacteria in people, helping doctors treat infections more effectively and tackle the issue of antibiotic resistance.
-
Developing tests to detect and identify infectious bacteria
This study is working on better tests to quickly and accurately find harmful bacteria that can make people sick, helping doctors give the right treatment sooner, especially for infections that are hard to treat.
-
Developing tests to detect and identify drug-resistant infections
This study is working on better tests to quickly and accurately find drug-resistant bacteria in people, so patients can get the right treatment faster and more effectively.
-
Investigating new treatments and prevention methods for infectious diseases.
This study is looking for people to try out new treatments and prevention methods for infectious diseases, so if you're interested in helping find better ways to fight these illnesses, this could be a great opportunity for you!
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.